We are live on ! Find out more
BCRX icon

BioCryst Pharmaceuticals
BCRX

134 hedge funds and large institutions have $245M invested in BioCryst Pharmaceuticals in 2020 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 52 increasing their positions, 38 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

671% more call options, than puts

Call options by funds: $3.05M | Put options by funds: $396K

37% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 38

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less funds holding

Funds holding: 136 → 134 (-2)

9.59% less ownership

Funds ownership: 89.1% → 79.51% (-9.6%)

48% less capital invested

Capital invested by funds: $473M → $245M (-$228M)

Holders
134
Holders Change
-2
Holders Change %
-1.47%
% of All Funds
2.95%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
26
Increased
52
Reduced
38
Closed
25
Calls
$3.05M
Puts
$396K
Net Calls
+$2.66M
Net Calls Change
+$1.39M

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$9.64M
2
Balyasny Asset Management
Balyasny Asset Management
Illinois
+$8.28M
3
EP
Eversept Partners
New York
+$7.26M
4
Stifel Financial
Stifel Financial
Missouri
+$5.76M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.5M

Top Sellers

Rank Fund Capital Flow
1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$14.8M
2
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$12.5M
3
Millennium Management
Millennium Management
New York
-$9.6M
4
PVI
Pura Vida Investments
New York
-$7.52M
5
ACP
Acuta Capital Partners
California
-$7.09M
Name Holding Trade Value Shares
Change 		Change in
Stake
CSS
101
Cubist Systematic Strategies
Connecticut
$39K +$46.8K +17,000 +654%
JG
102
Jefferies Group
New York
$38K -$815K -296,171 -94%
KM
103
Kalos Management
Georgia
$37K +$52.2K +18,950 New
Jacobs Levy Equity Management
104
Jacobs Levy Equity Management
New Jersey
$36K -$5.78M -2,098,317 -99%
AG
105
Aperio Group
California
$36K +$36 +13 +0.1%
Zurich Cantonal Bank
106
Zurich Cantonal Bank
Switzerland
$35K +$31.4K +11,392 +185%
Lazard Asset Management
107
Lazard Asset Management
New York
$35K +$48.2K +17,523 New
Rafferty Asset Management
108
Rafferty Asset Management
New York
$34K -$355K -128,884 -88%
C
109
Certuity
Florida
$30K – – –
ARTA
110
A.R.T. Advisors
New York
$26K +$35.9K +13,030 New
AIP
111
Ameritas Investment Partners
Nebraska
$25K – – –
Prudential Financial
112
Prudential Financial
New Jersey
$22K +$496 +180 +2%
DY
113
Dowling & Yahnke
California
$22K +$30.3K +11,000 New
T. Rowe Price Associates
114
T. Rowe Price Associates
Maryland
$21K -$7.25K -2,635 -20%
PPCM
115
Pillar Pacific Capital Management
California
$20K – – –
CWS
116
Cypress Wealth Services
California
$20K +$27.5K +10,000 New
EGM
117
Engineers Gate Manager
New York
$20K +$27.5K +10,000 New
Canada Life
118
Canada Life
Manitoba, Canada
$14K – – –
ASN
119
Advisory Services Network
Georgia
$11K – – –
HNB
120
Huntington National Bank
Ohio
$9K – – –
Rockefeller Capital Management
121
Rockefeller Capital Management
New York
$7K +$9.09K +3,300 New
PHK
122
Point72 Hong Kong
Hong Kong
$6K +$562 +204 +8%
NC
123
NewSquare Capital
Pennsylvania
$4K -$15.1K -5,500 -73%
Nisa Investment Advisors
124
Nisa Investment Advisors
Missouri
$4K +$5.42K +1,970 New
Bank of Montreal
125
Bank of Montreal
Ontario, Canada
$2K -$51.4K -18,679 -94%
3 4
5
6 7

BCRX Hedge Fund Activity: Q1 2020 in Review

134 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in BioCryst Pharmaceuticals (BCRX) for Q1 2020, worth a combined $245M — down 48% from $473M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new BCRX positions and 25 closed out — a net gain of 1 holder — while 52 added to existing stakes and 38 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $9.64M. The largest seller was Point72 Asset Management, cutting an estimated $14.8M.

  • 134 institutional investors held BioCryst Pharmaceuticals (BCRX) as of Q1 2020, down from 136 in Q4 2019.
  • Funds reported $245M of BioCryst Pharmaceuticals stock for Q1 2020, down 48% quarter-over-quarter.
  • 26 funds opened new BioCryst Pharmaceuticals positions in Q1 2020 and 25 closed out, a net change of +1 holder.
  • The largest BioCryst Pharmaceuticals buyer in Q1 2020 was Adage Capital Partners, an estimated $9.64M added.
  • The largest BioCryst Pharmaceuticals seller in Q1 2020 was Point72 Asset Management, an estimated $14.8M sold.

Based on aggregated 13F filings for Q1 2020.